Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
- PMID:33885977
- PMCID: PMC8137635
- DOI: 10.1007/s00535-021-01784-1
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Abstract
Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) and Crohn's disease (CD). Since 1950, the number of patients with IBD in Japan has been increasing. The etiology of IBD remains unclear; however, recent research data indicate that the pathophysiology of IBD involves abnormalities in disease susceptibility genes, environmental factors and intestinal bacteria. The elucidation of the mechanism of IBD has facilitated therapeutic development. UC and CD display heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management depends on the understanding and tailoring of evidence-based interventions by physicians. In 2020, seventeen IBD experts of the Japanese Society of Gastroenterology revised the previous guidelines for IBD management published in 2016. This English version was produced and modified based on the existing updated guidelines in Japanese. The Clinical Questions (CQs) of the previous guidelines were completely revised and categorized as follows: Background Questions (BQs), CQs, and Future Research Questions (FRQs). The guideline was composed of a total of 69 questions: 39 BQs, 15 CQs, and 15 FRQs. The overall quality of the evidence for each CQ was determined by assessing it with reference to the Grading of Recommendations Assessment, Development and Evaluation approach, and the strength of the recommendation was determined by the Delphi consensus process. Comprehensive up-to-date guidance for on-site physicians is provided regarding indications for proceeding with the diagnosis and treatment.
Keywords: Biologics; Immunomodulators; Inflammatory bowel disease; Steroid.
Conflict of interest statement
Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria or any other types of remuneration; Abbvie, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Takeda Pharmaceutical, Pfizer, Celgene, EA Pharma, Zeria Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Daiichi Sankyo, JIMRO, Alfressa Pharma, Gilead Sciences, and (2) those from which the authors have received scholarship/research grant; Nippon Kayaku, Takeda Pharmaceutical, Otsuka Pharmaceutical, Eisai, EA Pharma, Hoya Group Pentax Medical, Abbvie, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Janssen Pharmaceutical, EA Pharma, JIMRO, Zeria Pharmaceutical, Pfizer, Alfressa Pharma, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Gilead Sciences, Kissei Pharmaceutical, and (3) those from which the authors have received individually endowed chair; Mitsubishi Tanabe Pharma, EA Pharma, AbbVie, Janssen Pharmaceutical, Mochida Pharmaceutical, Takeda Pharmaceutical, Kyorin Holdings, JIMRO, Zeria Pharmaceutical, Otsuka Pharmaceutical.
Figures
Similar articles
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB.Lamb CA, et al.Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.Gut. 2019.PMID:31562236Free PMC article.Review.
- Evidence-based clinical practice guidelines for inflammatory bowel disease.Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T.Matsuoka K, et al.J Gastroenterol. 2018 Mar;53(3):305-353. doi: 10.1007/s00535-018-1439-1. Epub 2018 Feb 10.J Gastroenterol. 2018.PMID:29429045Free PMC article.
- Evidence-based clinical practice guidelines for management of colorectal polyps.Tanaka S, Saitoh Y, Matsuda T, Igarashi M, Matsumoto T, Iwao Y, Suzuki Y, Nozaki R, Sugai T, Oka S, Itabashi M, Sugihara KI, Tsuruta O, Hirata I, Nishida H, Miwa H, Enomoto N, Shimosegawa T, Koike K.Tanaka S, et al.J Gastroenterol. 2021 Apr;56(4):323-335. doi: 10.1007/s00535-021-01776-1. Epub 2021 Mar 12.J Gastroenterol. 2021.PMID:33710392Free PMC article.Review.
- Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.Yoshiji H, et al.J Gastroenterol. 2021 Jul;56(7):593-619. doi: 10.1007/s00535-021-01788-x. Epub 2021 Jul 7.J Gastroenterol. 2021.PMID:34231046Free PMC article.Review.
- British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease.Lomer MCE, Wilson B, Wall CL.Lomer MCE, et al.J Hum Nutr Diet. 2023 Feb;36(1):336-377. doi: 10.1111/jhn.13054. Epub 2022 Jul 21.J Hum Nutr Diet. 2023.PMID:35735908Free PMC article.
Cited by
- Effects of ulcerative colitis and Crohn's disease on neurodegenerative diseases: A Mendelian randomization study.Li H, Wen Z.Li H, et al.Front Genet. 2022 Aug 15;13:846005. doi: 10.3389/fgene.2022.846005. eCollection 2022.Front Genet. 2022.PMID:36046231Free PMC article.
- Thiopurines exert harmful effects on spermatogenesis in Nudt15R138C knock-in mice.Yokota Y, Imai T, Kawahara M, Inatomi O, Nishida A, Kakuta Y, Masamune A, Andoh A.Yokota Y, et al.J Gastroenterol. 2024 Feb;59(2):109-118. doi: 10.1007/s00535-023-02059-7. Epub 2023 Dec 15.J Gastroenterol. 2024.PMID:38097780
- Key Disease-Related Genes and Immune Cell Infiltration Landscape in Inflammatory Bowel Disease: A Bioinformatics Investigation.Alghamdi KS, Kassar RH, Farrash WF, Obaid AA, Idris S, Siddig A, Shakoori AM, Alshehre SM, Minshawi F, Mujalli A.Alghamdi KS, et al.Int J Mol Sci. 2024 Sep 9;25(17):9751. doi: 10.3390/ijms25179751.Int J Mol Sci. 2024.PMID:39273699Free PMC article.
- Serum Leucine-Rich α2 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis.Horiuchi I, Horiuchi A, Umemura T.Horiuchi I, et al.J Clin Med. 2022 Oct 28;11(21):6366. doi: 10.3390/jcm11216366.J Clin Med. 2022.PMID:36362594Free PMC article.
- Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms.Hayashi T, Kitamura K, Usami M, Miyazawa M, Nishitani M, Dejima A, Yamamoto M, Kawase S, Funaki M, Orita N, Nakagawa H, Morita K, Iida N, Seki A, Nio K, Kido H, Takayama H, Takeuchi Y, Yamada S, Takatori H, Shimada M, Saito H, Yamamoto D, Toyama T, Yamashita T.Hayashi T, et al.Inflamm Intest Dis. 2023 Oct 5;8(4):133-142. doi: 10.1159/000534001. eCollection 2023 Dec.Inflamm Intest Dis. 2023.PMID:38115911Free PMC article.
References
- Yoshida M, Kinoshita Y, Watanabe M, et al. JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines. J Gastroenterol. 2015;50:4–10. - PubMed
- Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23. - PubMed
- Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483. - PubMed
- Japan Intractable Diseases Information Center. 2020.https://www.nanbyou.or.jp/. Accessed 15 Dec 2020.
- Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2019;54:1070–1077. - PubMed
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources